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Neuraminidase inhibiting antibody responses in pigs differ between
influenza A virus N2 lineages and by vaccine type
Abstract
The neuraminidase (NA) protein of influenza A viruses (IAV) has important functional roles in the viral
replication cycle. Antibodies specific to NA can reduce viral replication and limit disease severity, but are not
routinely measured. We analyzed NA inhibiting (NI) antibody titers in serum and respiratory specimens of
pigs vaccinated with intramuscular whole-inactivated virus (WIV), intranasal live-attenuated influenza virus
(LAIV), and intranasal wild type (WT) IAV. NI titers were also analyzed in sera from an investigation of
piglet vaccination in the presence of passive maternally-derived antibodies. Test antigens contained
genetically divergent swine-lineage NA genes homologous or heterologous to the vaccines with mismatched
hemagglutinin genes (HA). Naïve piglets responded to WIV and LAIV vaccines and WT infection with
strong homologous serum NI titers. Cross-reactivity to heterologous NAs depended on the degree of genetic
divergence between the NA genes. Bronchoalveolar lavage specimens of LAIV and WT-immunized groups
also had significant NI titers against the homologous antigen whereas the WIV group did not. Piglets of
vaccinated sows received high levels of passive NI antibody, but their NI responses to homologous LAIV
vaccination were impeded. These data demonstrate the utility of the enzyme-linked lectin assay for efficient
NI antibody titration of serum as well as respiratory tract secretions. Swine IAV vaccines that induce robust
NI responses are likely to provide broader protection against the diverse and rapidly evolving IAV strains that
circulate in pig populations. Mucosal antibodies to NA may be one of the protective immune mechanisms
induced by LAIV vaccines.
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a b s t r a c t
The neuraminidase (NA) protein of influenza A viruses (IAV) has important functional roles in the viral
replication cycle. Antibodies specific to NA can reduce viral replication and limit disease severity, but
are not routinely measured. We analyzed NA inhibiting (NI) antibody titers in serum and respiratory
specimens of pigs vaccinated with intramuscular whole-inactivated virus (WIV), intranasal live-
attenuated influenza virus (LAIV), and intranasal wild type (WT) IAV. NI titers were also analyzed in sera
from an investigation of piglet vaccination in the presence of passive maternally-derived antibodies. Test
antigens contained genetically divergent swine-lineage NA genes homologous or heterologous to the vac-
cines with mismatched hemagglutinin genes (HA). Naïve piglets responded toWIV and LAIV vaccines and
WT infection with strong homologous serum NI titers. Cross-reactivity to heterologous NAs depended on
the degree of genetic divergence between the NA genes. Bronchoalveolar lavage specimens of LAIV and
WT-immunized groups also had significant NI titers against the homologous antigen whereas the WIV
group did not. Piglets of vaccinated sows received high levels of passive NI antibody, but their NI
responses to homologous LAIV vaccination were impeded. These data demonstrate the utility of the
enzyme-linked lectin assay for efficient NI antibody titration of serum as well as respiratory tract secre-
tions. Swine IAV vaccines that induce robust NI responses are likely to provide broader protection against
the diverse and rapidly evolving IAV strains that circulate in pig populations. Mucosal antibodies to NA
may be one of the protective immune mechanisms induced by LAIV vaccines.
Published by Elsevier Ltd.
1. Introduction
The neuraminidase (NA) protein of influenza A virus (IAV) has
sialidase activity that facilitates the release of new viral particles
from receptors on infected cells [1,2]. NA inhibitor drugs that bind
to the sialidase catalytic site are widely used therapeutics for influ-
enza patients [3]. Likewise, antibodies targeting NA have been cor-
related with reduced disease severity and viral replication in
animal models [4,5]. Human clinical studies have also shown evi-
dence for reduced disease severity in individuals with well-
matched circulating NI antibodies [6–8]. NA antibody-binding sites
undergo antigenic drift comparable to hemagglutinin (HA) anti-
genic drift [9,10], suggesting that NA-specific antibodies exert
selective pressure for mutations. Mechanisms for the protective
action of NA-specific antibodies were investigated soon after NA
enzymatic function was reported. Strain-matched NA antiserum
added to in vitro IAV culture reduced the virus yield from infected
cultures and reduced the size of plaques [11]. Electron microscopy
showed that NA-specific antiserum promotes aggregation of new
IAV viral particles on the surface of infected cells [2,12], hindering
the spread of virus to other cells.
Research characterizing NI antibody responses to vaccination
has been fairly limited in any host, especially concerning live-
attenuated influenza virus (LAIV) vaccines. Published studies of
NI responses in pigs are extremely limited. We hypothesized that
intranasal LAIV vaccines, like natural infection, elicits both local
and systemic NI antibodies. NI antibodies at the respiratory
mucosal surfaces might be particularly effective at reducing viral
replication in vivo. A recent study analyzed NI activity in nasal
http://dx.doi.org/10.1016/j.vaccine.2016.06.001
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secretions of human subjects before and after an influenza season
[8]. Nasal NI titers were statistically correlated with reduced sever-
ity of natural infection during the subsequent months. Another
recent clinical study identified an inverse correlation between
serum NI antibody responses induced by seasonal IAV vaccines
and the incidence of seasonal influenza infection [13]. In human
clinical studies it is usually not possible to discern whether pre-
existing NI antibodies were induced by infection or vaccination
or the combination. In human subjects it is also difficult to collect
specimens suitable to analyze influenza antibodies in the lungs.
Animal studies with natural IAV host species, such as pigs, offer
the possibility to measure local NI antibodies of the upper versus
lower respiratory tract.
Swine IAV is an economically important pathogen affecting pig
populations around the globe [14]. Swine IAV also has public
health significance, exemplified by the emergence of swine-
origin 2009 pandemic H1N1 virus and zoonotic H3N2 virus infec-
tions at agricultural fairs [15–17]. Furthermore, since the pig is a
natural IAV host, it is a valuable experimental model for testing
vaccines and immune parameters relevant to human IAV. There
are multiple IAV lineages co-circulating in pigs [14], belonging to
subtypes H1N1, H1N2, and H3N2. Hemagglutinins (HA) of the
swine H1 and H3 subtypes are genetically and antigenically diverse
[18,19]. There is also diversity in NA genes. Contemporary North
American swine N2 genes fall into two distinct lineages, one
acquired by reassortment with a human seasonal H3N2 strain
detected in pigs in 1998, and the other acquired by reassortment
with a more contemporary human seasonal H3N2 from about
2002 [20]. Thus, we also hypothesized that these distinct genetic
differences in N2 genes would alter antibody cross-reactivity direc-
ted against the NA proteins.
Current commercial vaccines against swine IAV (containing
whole inactivated virus (WIV) plus adjuvant) do not give reliable
protection against the diverse co-circulating viruses [21]. Intrana-
sal LAIV vaccines attenuated by several mutation strategies have
shown efficacy against experimental challenge with heterologous
strains [22–24], and in maternal antibody-positive piglets [25].
LAIV vaccines in swine have been shown to induce serum neutral-
izing antibodies, virus-binding IgA in the respiratory tract, and cell-
mediated immunity [26]. In the current study we quantified
vaccine-induced NI antibodies in serum and respiratory mucosal
specimens, examined the antigenic cross-reactivity between the
two phylogenetic lineages of N2 subtype NA, and analyzed NA-
specific maternal antibodies in piglets receiving colostrum from
vaccinated sows.
2. Materials and methods
2.1. Viruses
Virus strains used to generate vaccines were a delta-1 cluster
H1N2 isolate, A/swine/Minnesota/02011/2008 (MN08), and a
cluster I H3N2 isolate, A/swine/Texas/4199-2/1998 (TX98)
(Table 1). In experiment 1, pigs received heterologous challenge
infection with the 2009 pandemic strain A/California/04/2009
(H1N1). Test antigens for use in the NI assay consisted of viruses
derived by reverse genetics, by previously reported methods [27],
and cultivated in MDCK cells. The HA genes included in the
reverse-engineered NI antigens were intentionally mismatched to
the HA in the vaccine viruses to rule out antibodies binding to
HA at the virus surface and interfering non-specifically with NA
function. One virus (H9N2MN08) was a reassortant containing the
six internal gene segments of A/Puerto Rico/8/1934, the HA gene
of A/guinea fowl/Hong Kong/WF10/1999 (HK99)(H9N2), and the
NA gene of MN08, representing the 1998 N2 lineage. A second
reassortant virus (H9N2OH04) had the HA gene of HK99 and all
other gene segments of OH04, including NA of the 2002 N2 lineage.
A third reassortant virus (H1N2TX98) contained the six internal
gene segments and HA of A/Puerto Rico/8/1934 and the NA gene
of TX98.
2.2. Experimental design
2.2.1. Vaccination experiment 1
MN08 vaccines were administered as previously described [28].
Briefly, an LAIV vaccine was generated using reverse genetics to
insert the MN08 H1 and N2 gene segments into the attenuated
A/turkey/Ohio/313053/04 (OH04) backbone [24]. Immunization
by wild type (WT) virus infection was done using live MN08. The
whole inactivated virus (WIV) vaccine was UV-irradiated MN08
mixed with a commercial oil-in-water adjuvant (Emulsigen D;
MVP Laboratories, Inc., Ralston, NE). The sham vaccine (SV) was
prepared from cell culture supernatant mixed with Emulsigen D.
Pigs were cared for in accordance with the Institutional Animal
Care and Use Committee (IACUC) of the National Animal Disease
Center. Experimental groups received two doses of their respective
vaccine at 4 and 7 weeks of age. Those in the LAIV and WT groups
were vaccinated intranasally with 2 ml of virus at 106 50% tissue
culture infectious doses (TCID50) per ml. The WIV vaccinated pigs
were administered 2 ml (128 HA units) of inactivated, adjuvanted
vaccine by intramuscular injection. Negative controls received 2 ml
of SV by the same route. The sera tested by enzyme-linked lectin
assay (ELLA) were collected 6 weeks post-primary vaccination
and heat-inactivated at 56 C for 30 min. Pre-challenge bron-
choalveolar lavage (BAL) fluid and nasal wash (NW) samples were
collected from subgroups of pigs (n = 8) that were humanely
euthanized 6 weeks post-primary vaccination. Remaining pigs in
each group (n = 8) were challenged 6 weeks post-primary
vaccination by intranasal infection with A/California/04/2009 at
1  103 TCID50/ml. These pigs were euthanized and BAL fluid was
collected at 5 days post-infection (dpi) to compare pre- and post-
challenge NI responses to heterologous challenge. Fifty ml MEM
was pipetted into lungs via the trachea, followed by a series of
3–4 repeated lavages, and approximately 15–20 ml recovered in
Table 1
Summary of the components of vaccine, challenge and neuraminidase inhibition test viruses.
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the final specimen. BAL fluid specimens from infected pigs were
incubated with turkey erythrocytes on ice to absorb virus that
might affect the ELLA readout.
2.2.2. Vaccination experiment 2
As described previously [26], piglets with or without vaccine-
matched passive maternal antibodies were immunized with WIV
or LAIV vaccines. Briefly, sows were vaccinated intramuscularly
with Emulsigen D-adjuvanted TX98 WIV in 3 doses, before and
during pregnancy. Co-housed control sows received no IAV vac-
cine. After farrowing, one week-old piglets were bled to collect
serum and confirm transfer of IAV-specific maternal antibodies.
At 14–19 days of age piglets were weaned and randomly assigned
to vaccine treatment groups within the appropriate maternally
derived antibody (MDA) status, and initial doses of WIV as given
to the sows or LAIV were given at 15–20 days of age. The TX98 LAIV
was generated via reverse genetics as previously described [29],
with the NS1 gene truncated to encode 126 amino acids. Piglets
were immunized with 2 ml of LAIV at 106 TCID50/ml intranasally
or 2 ml WIV intramuscularly. Booster doses were administered
2 weeks later to the WIV and LAIV groups.
2.3. Enzyme-linked lectin assay (ELLA) for neuraminidase antibodies
Serum and BAL fluid neuraminidase inhibition (NI) titers were
measured using an assay described previously [30,31]. Briefly, NA
enzymatic activity of a virus was quantified by sialic acid cleavage
from fetuin on 96-well plates during an overnight incubation at
37 C. Peanut agglutinin-horseradish peroxidase conjugate (PNA-
HRP) was then added for 2 h at room temperature, binding to
fetuin molecules stripped of sialic acid. Signal was obtained with
O-phenylenediamine dihydrochloride (OPD) substrate, and read
at 490 nm. Test antigens were titrated to determine the highest
dilution able to yield maximum signal. For NI antibody titration,
serial dilutions of serum or BAL fluid were mixed with virus at
equal volumes in duplicate fetuin-coated wells during the over-
night 37 C incubation. Optical density (OD) values were normal-
ized to the values from positive control wells containing no
serum. Non-linear regression, with log2 transformed serum dilu-
tions as the independent variable, was performed to calculate the
serum dilution that would inhibit 50% of NA activity (IC50) (Graph-
Pad Prism software). Spearman correlation coefficients were calcu-
lated for homologous HI and NI titers within each treatment group
from vaccination experiment 1, using GraphPad Prism software.
Statistical significance of correlation was determined with a two-
tailed p-value (a = 0.05).
3. Results
3.1. Neuraminidase antibodies induced by vaccination
In the first vaccination experiment we administered WIV and
LAIV vaccines and the WT virus to naïve piglets (Table 1). Viruses
in each vaccine formulation carried the NA gene of A/swine/
Minnesota/02011/2008 (MN08) (H1N2). NAMN08 belongs to the
1998 N2 lineage (Fig. 1). Groups that were immunized with WIV,
LAIV, or WT virus had robust serum NI responses to the homolo-
gous NA antigen (Fig. 2A). The background titers in sham-
vaccinated animals ranged between 5 and 40. In contrast, all three
immunized groups developed geometric mean homologous NI
titers between 640 and 1280. The highest and most consistent
response was in piglets infected with live WT MN08, but there
were no statistically significant differences among the immunized
groups. All of the vaccines also induced robust homologous HI
antibody responses, and the homologous NI titers were plotted
against homologous HI titers (Fig. 3). In the LAIV and WT groups
there were statistically significant correlations between NI and HI
titers, with r values of 0.609 (p = 0.0140) and 0.523 (p = 0.0385),
respectively. However, the WIV vaccinated group displayed more
variability in the NI response compared to the HI response,
resulting in a non-significant r value of 0.425 (p = 0.102). The
WIV vaccine dose was standardized to units of HA activity, and
since the inactivated viruses do not replicate to increase the NA
protein quantity, the response to the WIV was likely biased toward
the HA.
NI titers were also determined against two heterologous NA
antigens. NA of the H3N2 strain A/swine/Texas/4199-2/1998
(TX98) also belongs to the 1998 N2 lineage, but it preceded the
N2 of the MN08 by ten years and shared 96.8% amino acid
sequence identity with the NAMN08 present in the experimental
vaccines (Fig. 1). Cross-reactive serum antibodies to NATX98 were
readily detectable in all MN08-immunized groups (Fig. 2B). The
geometric mean titer in those three groups was slightly below
160, with heterologous NI titers generally 4-to 8-fold lower than
homologous titers to NAMN08. The other heterologous antigen con-
tained NA of the H3N2 strain A/turkey/Ohio/313053/04 (OH04),
which falls into the 2002 N2 lineage (Fig. 1). The NA amino acid
sequence identity between OH04 and the vaccine strain, MN08,
is 91.9%. Cross-reactive serum NI titers against NAOH04 were mostly
undetectable (Fig. 2C).
BAL fluid and nasal wash specimens were collected 6 weeks
post-primary vaccination from the same pigs as the sera. In pigs
vaccinated with intramuscular WIV or sham vaccine, BAL fluid NI
titers were not detectable (Fig. 4A). In contrast, groups that had
been exposed to live LAIV or WT MN08 virus via the respiratory
route developed homologous NI titers in lungs. The results were
very similar between the LAIV and WT groups, with geometric
mean titers of 23.8 and 27.2, respectively. In these groups there
was considerable variation, with titers ranging from near the lower
limit of detection (5) to above 100. Cross-reactive NI titers to the
heterologous NAOH04 antigen, representing the 2002 N2 lineage,
were essentially undetectable in BAL fluid specimens (data not
shown). Other pigs in each of the four treatment groups underwent
heterologous challenge with CA09 (pandemic H1N1), with out-
comes reported previously [28]. With respect to NA proteins this
was a heterosubtypic challenge virus, but we asked if IAV infection
of vaccinated pigs would increase MN08-specific NI antibodies in
the lungs. Titration of 5 dpi BAL fluid showed that geometric mean
NI titers in lungs of the LAIV and WT groups reached considerably
higher levels than before challenge: 256 and 429, respectively
(Fig. 4B). Modest NI titers also appeared in BAL fluid of WIV-
vaccinated, CA09-infected pigs, but the geometric mean titer
remained below 20.
Nasal washing is more practical for routine sampling of the res-
piratory mucosa, as it is performed without euthanizing or anes-
thetizing pigs, so we tested whether NI titers were present in
nasal secretions (Fig. 4C). Nasal wash specimens from immunized
pigs had relatively weak NI reactivity against the homologous
NAMN08 antigen. There was a statistically insignificant trend for
higher nasal NI activity in the LAIV andWT virus treatment groups,
where most of the animals had titers of at least 10. In contrast, a
titer of 10 was recorded for only one WIV-vaccinated pig and none
of the SV controls. Only the WT MN08 group had nasal NI activity
statistically different from the SV control group, albeit a modest
difference, with geometric mean titers of 12.0 and 7.9, respectively.
Background NI activity of nasal wash samples was higher than in
BAL fluid. In all, there was evidence that NI antibodies can be
detected in the upper respiratory tract after pigs are exposed to a
live virus, but titers there are lower in magnitude and more diffi-
cult to distinguish from background inhibition.
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3.2. Passive maternally-derived neuraminidase antibodies
A second vaccine study quantified NA-specific maternal anti-
bodies in piglets and also tested the impact of passive, maternal
immunity on active NI antibody responses to vaccination. Sows
were immunized before and during gestation with WIV vaccines
containing the TX98 strain. Piglets from WIV vaccinated sows
obtained abundant amounts of circulating NI antibody (Fig. 5A).
On the day of weaning and LAIV vaccination, when piglets were
15–20 days of age, the geometric mean serum NI titer was 2417.
The background serum inhibition of piglets from naïve sows was
very low. Likewise, serum hemagglutination inhibition (HI) titers
were abundant in piglets of the vaccinated sows and undetectable
in piglets from naïve sows [26]. The NI assay was repeated with
serum specimens collected 42 days later, after piglets had received
1 or 2 doses of TX98 LAIV vaccine. In the non-vaccinated (NV)
group the high passive NI antibody titers had waned markedly dur-
ing those 6 weeks to mostly undetectable levels (Fig. 5B); this was
comparable to the waning of HI titers reported previously [26].
Maternal antibodies partially blocked serum NI responses to intra-
nasal LAIV vaccination (Fig. 5B). Even in maternal antibody-
negative groups, the serum NI responses to 1 or 2 doses of LAIV
vaccine were modest (geometric mean titers of 36.6 and 32.8,
respectively), but they were significantly higher than titers of their
maternal antibody-positive counterparts and the non-vaccinated
groups.
4. Discussion
Inactivated IAV vaccines licensed for humans and for pigs
induce circulating antibodies that neutralize antigenically identical
Fig. 1. N2 genes representing two neuraminidase lineages in North American swine since 1998. Included in the maximum likelihood tree are N2 genes of five human strains
selected for contemporaneous seasonal influenza vaccines. The three swine strains supplying N2 antigens for NI assays in this study are printed in bold.
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or similar strains, while offering limited protection against anti-
genic drift variants and newly emerged strains. LAIV vaccines have
shown the ability to protect against divergent strains in humans
[32]. Challenge studies in several animal hosts also show the pro-
tective efficacy of LAIV vaccines against homologous and heterolo-
gous IAV infections [25,33]. Data from pig experiments indicate
that intranasal LAIV vaccines induce mucosal immunity, e.g.
virus-specific IgA and neutralizing antibodies in the upper and
lower respiratory tract [22,23]. NI antibodies are potentially an
important component of LAIV-induced immunity, which might
compliment the neutralizing action of HA-binding antibodies,
especially when HA antigenic drift occurs. Thus far, there are few
published studies describing LAIV induction of NI antibodies in fer-
rets [34] and humans [8].
Homologous and cross-reactive NI antibodies in serum and res-
piratory specimens from pigs immunized with WT virus, LAIV, or
WIV were measured. We determined that robust homologous
serum NI responses were attained from each of the immunization
regimens. Varying levels of NI activity against phylogenetically dis-
tinct N2 proteins within the 1998 lineage and more profoundly
Fig. 2. Functional serum NI antibodies in pigs following vaccination or infection. Three weeks after the administration of secondary doses (six weeks post-primary
vaccination) sera were collected. NI antibody titers to the homologous 1998-lineage N2MN08 (A), heterologous 1998-lineage N2TX98 (B), and heterologous 2002-lineage N2OH04
(C) proteins were determined by the ELLA method, using reverse genetics-derived reassortant viruses as test antigens. Titers represent 50% enzymatic inhibition endpoints as
calculated by nonlinear regression. Data were analyzed statistically by ANOVA and Tukey’s pairwise comparison test. Treatment groups marked with different letters had
significantly different titers (p < 0.05).
Fig. 3. Comparison of homologous neuraminidase inhibition titers to homologous hemagglutination inhibition titers. For each vaccine treatment group in experiment 1,
serum NI titers to homologous 1998-lineage N2MN08 antigen were plotted against the corresponding homologous HI titers. In the LAIV, WT, and WIV vaccinated groups there
were Spearman correlation coefficients of 0.609 (p = 0.0140), 0.523 (p = 0.0385), and 0.425 (p = 0.102), respectively.
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between the 1998 and 2002 lineages were found in all immunized
groups. The heterologous 1998-lineage N2, with 97% amino acid
identity to the vaccine strain, demonstrated moderately lower
cross-reactive NI titers. When the sera were assayed against a
2002-lineage N2, with about 92% amino acid identity, virtually
no NI cross-reactivity could be detected. WIV vaccines containing
N2 only of the 1998 lineage appear unlikely to elicit significant
NI cross-reactivity against 2002-lineage strains.
Fig. 4. Mucosal NI antibodies in pigs following vaccination or experimental infection. Three weeks after the secondary doses (six weeks post-primary vaccination), a subset of
pigs were sacrificed. Bronchoalveolar lavage fluid (BALF) and nasal wash (NW) specimens were collected. Five days post-infection of the remaining pigs, they were euthanized
and BALF specimens were collected. NI antibody titers to the homologous 1998-lineage N2MN08 protein were determined in pre-challenge BALF (A), post-challenge BALF (B),
and pre-challenge NW (C). Data were analyzed statistically by ANOVA and Tukey’s pairwise comparison test. Treatment groups marked with different letters had significantly
different titers (p < 0.05).
Fig. 5. Passive and adaptive serum NI antibodies measured in colostrum-fed piglets. Sows were vaccinated, before and during gestation, with a total of three doses of WIV;
non-vaccinated control sows remained seronegative for IAV. Groups of piglets that suckled vaccinated sows are labeled as maternally-derived antibody positive [MDA(+)]. At
0 days post-vaccination (dpv) (15–20 days of age), piglets were bled for serum and designated groups were vaccinated intranasally with LAIV. Both of the LAIVx2 groups
received secondary doses of LAIV at 21 dpv. Serum samples collected at 0 dpv (A) and 42 dpv (B) were tested for NI titers against N2TX98 protein, which is homologous to the
sows’ WIV vaccine and the piglets’ LAIV vaccine. Data were analyzed statistically by ANOVA and Tukey’s pairwise comparison test. Treatment groups marked with different
letters had significantly different titers (p < 0.05).
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Mucosal NI antibody responses were limited to the treatment
groups exposed intranasally to live virus (LAIV or WT), despite
the high serum NI titers in WIV vaccinated pigs. The WIV vaccine
failed to induce respiratory tract NI antibodies; even 5 days after
heterologous challenge infection the influx of NI antibodies to
the lungs of WIV vaccinated pigs was modest. The LAIV and WT
groups, in contrast, had robust NI activity in BAL fluid specimens
and faint NI activity in NW, which is consistent with our previous
data for whole virus-binding IgA [26,28]. Five days after heterolo-
gous challenge infection the LAIV and WT groups had pronounced
increases in BAL fluid NI activity, presumably indicating an influx
of antibodies from the circulation to the lung.
The mucosal response to a live virus includes functional NI anti-
bodies, emphasizing that LAIV vaccines, as well as other platforms,
should contain NA genes matched to the prominent circulating IAV
strains in addition to updated HA genes. This is standard for human
seasonal LAIV vaccines, as each component normally contains HA
and NA of the approved reference strain. If circulating viruses then
undergo HA antigenic drift while the NA antigen remains static
[35], NA immunity may provide a level of protection. This is con-
siderably different for swine vaccines in the US, where more viral
lineages are co-circulating, strain updates to the commercial vacci-
nes are infrequent, and no LAIV vaccines are presently licensed.
Our results support inclusion of swine IAV strains with N2 genes
of both the 1998 lineage and the 2002 lineage, since the two lin-
eages co-circulate and have antigenic divergence. The presence of
up-to-date NA antigens in LAIV or inactivated vaccines improves
the likelihood of protection against antigenic drift variants and
novel emerging strains.
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